Teixeira R M, Santos A R, Ribeiro S J, Calixto J B, Rae G A, De Lima T C
Department of Pharmacology, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
Eur J Pharmacol. 1996 Sep 5;311(1):7-14. doi: 10.1016/0014-2999(96)00390-1.
This study assessed the effects of intracerebroventricular administration of selective agonists and antagonists for tachykinin NK1 and NK2 receptors on performance of mice in the elevated plus-maze, an ethological model of anxiety. Mice were treated with either vehicle (5 microliters) or 1, 10, 100 or 500 pmol of substance P, neurokinin A, the selective NK1 receptor agonist substance P methyl ester, or the selective NK2 receptor agonist, [beta-Ala8]neurokinin A-(4-10). Other mice received similar doses of FK 888, i.e., N2-[(4R)-4-hydroxy-1-(1-methyl-1 H-indol-3-y)carbonyl-L-prolyl]-N-methyl-N-phenylmethyl-3-(2-naphthyl)-L- alaninamide, or SR 48968, i.e., (S)-N-methyl-(N-[4-acetylamine-4-phenylpiperidine)-2-(3, 4-dichlorophenyl)buthyl]benzamide, selective antagonists of tachykinin NK1 and NK2 receptors, respectively. Injections of substance P, neurokinin A, substance P methyl ester or [beta-Ala8]neurokinin A-(4-10) significantly reduced the frequency of open arm entries, and [beta-Ala8]neurokinin A-(4-10) also enhanced the percentage of entries into enclosed arms. Conversely, the NK1 antagonist FK 888 and the NK2 antagonist SR 48968 each increased the time spent in the open arms, and SR 48968 also increased the frequency of entries into the open arms. None of the tachykinin receptor agonists or antagonists modified motor performance and coordination on the rotarod apparatus or ambulation in an activity cage. Together, these results suggest that centrally administered NK1 and NK2 receptor agonists and antagonists can modulate anxiety, as evaluated in the elevated plus-maze test in mice. Stimulation of either tachykinin NK1 or NK2 receptors induces anxiogenic-like responses, whereas the reverse occurs following their blockade. The anxiolytic-like profiles of action of both tachykinin NK1 and NK2 receptor antagonists suggest that central tachykinin mechanisms are tonically involved in the modulation of anxiety.
本研究评估了脑室内注射速激肽NK1和NK2受体的选择性激动剂和拮抗剂对小鼠在高架十字迷宫(一种焦虑行为学模型)中行为表现的影响。给小鼠注射溶剂(5微升)或1、10、100或500皮摩尔的P物质、神经激肽A、选择性NK1受体激动剂P物质甲酯或选择性NK2受体激动剂[β - 丙氨酸8]神经激肽A -(4 - 10)。其他小鼠接受类似剂量的FK 888,即N2 - [(4R)-4 - 羟基 - 1 -(1 - 甲基 - 1H - 吲哚 - 3 - 基)羰基 - L - 脯氨酰] - N - 甲基 - N - 苯基甲基 - 3 -(2 - 萘基)-L - 丙氨酰胺,或SR 48968,即(S)-N - 甲基 -(N - [4 - 乙酰氨基 - 4 - 苯基哌啶)-2 -(3,4 - 二氯苯基)丁基]苯甲酰胺,分别为速激肽NK1和NK2受体的选择性拮抗剂。注射P物质、神经激肽A、P物质甲酯或[β - 丙氨酸8]神经激肽A -(4 - 10)显著降低了进入开放臂的频率,并且[β - 丙氨酸8]神经激肽A -(4 - 10)还增加了进入封闭臂的百分比。相反,NK1拮抗剂FK 888和NK2拮抗剂SR 48968均增加了在开放臂中停留的时间,并且SR 48968还增加了进入开放臂的频率。速激肽受体激动剂或拮抗剂均未改变小鼠在转棒试验中的运动表现和协调性或在活动笼中的行走情况。总之,这些结果表明,如在小鼠高架十字迷宫试验中所评估的,中枢给予NK1和NK2受体激动剂和拮抗剂可调节焦虑。刺激速激肽NK1或NK2受体均诱导焦虑样反应,而阻断这些受体则产生相反的效果。速激肽NK1和NK2受体拮抗剂的抗焦虑样作用模式表明,中枢速激肽机制持续参与焦虑的调节。